Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2015-11-09
|
vantictumab (anti-Fzd7, OMP-18R5) |
non-small cell lung cancer (NSCLC) |
preclinical |
OncoMed Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2015-11-09
|
navicixizumab - anti-DLL4/VEGF bispecific (OMP-305B83) |
|
preclinical |
OncoMed Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2015-11-09
|
interleukin-18 binding protein (IL-18BP) |
systemic inflammation |
|
AB2 Bio (Switzerland) |
Inflammatory diseases |
2015-11-08
|
sarilumab (REGN88/SAR153191) |
rheumatoid arthritis |
3 |
Sanofi (France) Regeneron Pharmaceuticals (USA - NY) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2015-11-08
|
GLPG0634 (filgotinib) |
rheumatoid arthritis |
2b |
Galapagos (Belgium) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2015-11-07
|
Soliris® (eculizumab) |
atypical hemolytic uremic syndrome (aHUS) |
|
Alexion Pharmaceuticals (USA - CT) |
Rare diseases - Kidney diseases |
2015-11-07
|
enoblituzumab (MGA271) |
cancers expressing B7-H3 in the tumor and/or tumor-associated vasculature |
1 |
Macrogenics (USA - MD) |
Cancer - Oncology |
2015-11-06
|
AFM21 and AFM22 (NK- and T-cell TandAbs generated against EGFRvIII) |
|
preclinical |
Affimed (Germany) |
Autoimmune diseases |
2015-11-06
|
MI130004 |
HER2-expressing tumors |
preclinical |
PharmaMar (Spain) |
Cancer - Oncology |
2015-11-06
|
triheptanoin (UX007) |
Glut1 DS - Encephalopathy due to GLUT1 deficiency |
3 |
Ultragenyx Pharmaceutical (USA - CA) |
Rare diseases - CNS diseases - Neurological diseases |
2015-11-06
|
BI 695501 (biosimilar version of Humira® (adalimumab)) |
|
1 |
Boehringer Ingelheim (Germany) |
Autoimmune diseases – Dermatological diseases - Inflammatory diseases - Rheumatic diseases |
2015-11-05
|
RXI-109 |
prevention of the progression of retinal scarring in patients with advanced neovascular age-related macular degeneration |
1-2 |
RXi Pharmaceuticals (USA - MA) |
Ophtalmological diseases |
2015-11-05
|
ABT-555 |
relapsing forms of multiple sclerosis (RFMS) |
1 |
Abbvie (USA - IL) |
Neurodegenerative diseases |
2015-11-05
|
Paclical® (paclitaxel) |
metastatic breast cancer |
|
Oasmia Pharmaceutical (Sweden) |
Cancer - Oncology |
2015-11-05
|
UCART19 |
refractory relapsed Acute Lymphoblastic Leukemia (ALL) following mismatched allogeneic stem cell transplantation |
|
Cellectis (France) Great Ormond Street Hospital (GOSH) (UK) University College London (UCL) (UK) |
Cancer - Oncology |
2015-11-04
|
BioChaperone® Combo |
type 1 diabetes, type 2 diabetes |
1b |
Adocia (France) |
Metabolic diseases |
2015-11-04
|
|
|
|
Acucela (USA - MA) |
Ophtalmological diseases |
2015-11-04
|
|
Charcot-Marie-Tooth disease type 2D (CMT2D) |
|
Atyr Pharma (USA - CA) |
Rare diseases - Genetic diseases - Neurological diseases |
2015-11-03
|
Debio 1143 |
squamous non-small cell lung cancer (NSCLC), platinum-refractory ovarian cancer, basal-like/claudin low triple negative breast cancer |
1 |
Debiopharm (Switzerland) |
Cancer - Oncology |
2015-11-03
|
LY3127804 |
advanced solid tumors |
1 |
Eli Lilly (USA - IN) |
Cancer - Oncology |